S. Dubrov, M. Denysiuk, S. Sereda, V. Borisova, G. Slavuta, Y. Zaikin, S. Cherniaiev
{"title":"静脉注射免疫球蛋白在COVID-19重症患者综合治疗中的应用系列临床病例","authors":"S. Dubrov, M. Denysiuk, S. Sereda, V. Borisova, G. Slavuta, Y. Zaikin, S. Cherniaiev","doi":"10.25284/2519-2078.1(94).2021.230620","DOIUrl":null,"url":null,"abstract":"Introduction. The incidence of COVID-19 continues to rise rapidly worldwide, leading to significant socio-economic damage to health and economic systems.Objective. To determine the effectiveness of intravenous immunoglobulin G (IVIG) in combination with a basic therapy in severe COVID-19.Materials and methods. A retrospective cohort study of 8 case histories of patients with severe COVID-19 for the period from 27.08.2020 to 20.03.2021 was conducted in the intensive care unit (ICU) of the infectious diseases department of the Municipal Non-Profit Enterprise «Kyiv City Clinical Hospital №17» (MNE KCCH №17).Results and discussions. During the period from 27.08.20 to 20.03.21 in the intensive care unit (ICU) of the infectious department of the Municipal Non-Profit Enterprise «Kyiv City Clinical Hospital №17» (MNE KCCH №17) there were 163 patients, of whom 79 died and the mortality rate was 48.4%. The mean age of patients was 63.5 ± 12.9 years (19 to 95 years). The mean age of death was 66.9 ± 9.9 years (40 to 87 years).During the study period, 8 patients received IVIG (5%) together with a basic therapy. The mean age of patients was 51.4 ± 14.7 years (from 29 to 69 years). Mortality among patients receiving IVIG was 37.5%.Conclusions. Mortality of patients who received IVIG in addition to a basic therapy was significantly lower compared to patients who received only basic therapy, 37.5% and 48.4%, respectively.","PeriodicalId":7735,"journal":{"name":"Anaesthesia, Pain & Intensive Care","volume":"41 1","pages":""},"PeriodicalIF":0.2000,"publicationDate":"2021-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"USE OF INTRAVENOUS IMMUNOGLOBULIN G IN COMPREHENSIVE TREATMENT OF COVID-19 SEVERE PATIENTS. SERIES OF CLINICAL CASES\",\"authors\":\"S. Dubrov, M. Denysiuk, S. Sereda, V. Borisova, G. Slavuta, Y. Zaikin, S. Cherniaiev\",\"doi\":\"10.25284/2519-2078.1(94).2021.230620\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction. The incidence of COVID-19 continues to rise rapidly worldwide, leading to significant socio-economic damage to health and economic systems.Objective. To determine the effectiveness of intravenous immunoglobulin G (IVIG) in combination with a basic therapy in severe COVID-19.Materials and methods. A retrospective cohort study of 8 case histories of patients with severe COVID-19 for the period from 27.08.2020 to 20.03.2021 was conducted in the intensive care unit (ICU) of the infectious diseases department of the Municipal Non-Profit Enterprise «Kyiv City Clinical Hospital №17» (MNE KCCH №17).Results and discussions. During the period from 27.08.20 to 20.03.21 in the intensive care unit (ICU) of the infectious department of the Municipal Non-Profit Enterprise «Kyiv City Clinical Hospital №17» (MNE KCCH №17) there were 163 patients, of whom 79 died and the mortality rate was 48.4%. The mean age of patients was 63.5 ± 12.9 years (19 to 95 years). The mean age of death was 66.9 ± 9.9 years (40 to 87 years).During the study period, 8 patients received IVIG (5%) together with a basic therapy. The mean age of patients was 51.4 ± 14.7 years (from 29 to 69 years). Mortality among patients receiving IVIG was 37.5%.Conclusions. Mortality of patients who received IVIG in addition to a basic therapy was significantly lower compared to patients who received only basic therapy, 37.5% and 48.4%, respectively.\",\"PeriodicalId\":7735,\"journal\":{\"name\":\"Anaesthesia, Pain & Intensive Care\",\"volume\":\"41 1\",\"pages\":\"\"},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2021-03-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Anaesthesia, Pain & Intensive Care\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.25284/2519-2078.1(94).2021.230620\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ANESTHESIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anaesthesia, Pain & Intensive Care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25284/2519-2078.1(94).2021.230620","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ANESTHESIOLOGY","Score":null,"Total":0}
USE OF INTRAVENOUS IMMUNOGLOBULIN G IN COMPREHENSIVE TREATMENT OF COVID-19 SEVERE PATIENTS. SERIES OF CLINICAL CASES
Introduction. The incidence of COVID-19 continues to rise rapidly worldwide, leading to significant socio-economic damage to health and economic systems.Objective. To determine the effectiveness of intravenous immunoglobulin G (IVIG) in combination with a basic therapy in severe COVID-19.Materials and methods. A retrospective cohort study of 8 case histories of patients with severe COVID-19 for the period from 27.08.2020 to 20.03.2021 was conducted in the intensive care unit (ICU) of the infectious diseases department of the Municipal Non-Profit Enterprise «Kyiv City Clinical Hospital №17» (MNE KCCH №17).Results and discussions. During the period from 27.08.20 to 20.03.21 in the intensive care unit (ICU) of the infectious department of the Municipal Non-Profit Enterprise «Kyiv City Clinical Hospital №17» (MNE KCCH №17) there were 163 patients, of whom 79 died and the mortality rate was 48.4%. The mean age of patients was 63.5 ± 12.9 years (19 to 95 years). The mean age of death was 66.9 ± 9.9 years (40 to 87 years).During the study period, 8 patients received IVIG (5%) together with a basic therapy. The mean age of patients was 51.4 ± 14.7 years (from 29 to 69 years). Mortality among patients receiving IVIG was 37.5%.Conclusions. Mortality of patients who received IVIG in addition to a basic therapy was significantly lower compared to patients who received only basic therapy, 37.5% and 48.4%, respectively.